2022
Association of sarcoidosis with psoriasis: a cross-sectional study in the All of Us research program
Murphy M, Leasure A, Damsky W, Cohen J. Association of sarcoidosis with psoriasis: a cross-sectional study in the All of Us research program. Archives Of Dermatological Research 2022, 315: 1439-1441. PMID: 36436011, DOI: 10.1007/s00403-022-02488-z.Peer-Reviewed Original ResearchConceptsCross-sectional studyMatched cross-sectional studyAssociation of sarcoidosisCoexistence of sarcoidosisCommon genetic susceptibilitySimilar immunopathogenesisCardiopulmonary symptomsPsoriasis patientsInflammatory skinMultivariable analysisSystemic diseasePsoriasis casesProgram databaseImmune responseSarcoidosisPsoriasisUs Research ProgramPotential associationGenetic susceptibilityDiseaseImmunopathogenesisAssociationSame individualFurther researchTh1
2019
Janus kinase inhibition induces disease remission in cutaneous sarcoidosis and granuloma annulare
Damsky W, Thakral D, McGeary MK, Leventhal J, Galan A, King B. Janus kinase inhibition induces disease remission in cutaneous sarcoidosis and granuloma annulare. Journal Of The American Academy Of Dermatology 2019, 82: 612-621. PMID: 31185230, PMCID: PMC7590533, DOI: 10.1016/j.jaad.2019.05.098.Peer-Reviewed Original ResearchConceptsGranuloma annulareCutaneous sarcoidosisPathway activationCutaneous granulomatous disordersRecalcitrant cutaneous sarcoidosisSkin biopsy specimensSignal regulatory protein αJAK-STAT pathway activationTranscription (JAK/STAT) pathway activationRegulatory protein αRecalcitrant sarcoidosisSarcoidosis activityDisease remissionConsecutive patientsGranulomatous disorderProspective evaluationBiopsy specimensHistologic resolutionSkin biopsiesMean improvementSarcoidosisImmunohistochemical analysisJAK inhibitorsJAK inhibitionPatients
2018
Tofacitinib Treatment and Molecular Analysis of Cutaneous Sarcoidosis
Damsky W, Thakral D, Emeagwali N, Galan A, King B. Tofacitinib Treatment and Molecular Analysis of Cutaneous Sarcoidosis. New England Journal Of Medicine 2018, 379: 2540-2546. PMID: 30586518, PMCID: PMC6351852, DOI: 10.1056/nejmoa1805958.Peer-Reviewed Original ResearchConceptsCutaneous sarcoidosisPathogenesis of sarcoidosisSkin lesion samplesJAK inhibitor tofacitinibHistologic remissionSystemic glucocorticoidsImmunohistochemical testingImmunohistochemical examinationInhibitor tofacitinibSarcoidosisSkin diseasesPatientsLesion samplesJAK-STATJanus kinaseTranscription (STAT) signalingSequencing of RNASignal transducerTreatmentMolecular analysisRemissionMedicationsTofacitinibGlucocorticoidsPathogenesis